COMMUNIQUÉ DE PRESSE publié le 06/02/2024 à 15:02, il y a 7 mois 12 jours Original-Research: Sernova Corp (von First Berlin Equity Research GmbH): Buy First Berlin Equity Research has reiterated its BUY rating and CAD 3.80 price target for Sernova Corp (ISIN: CA81732W1041) based on the company's financial statement release and business update for FY 22/23. Sernova's achievements in diabetes treatment and potential partnering deal are anticipated to drive stock performance First Berlin Equity Research Sernova Corp FY 22/23 Diabetes Treatment Partnering Deal
COMMUNIQUÉ DE PRESSE publié le 19/10/2023 à 15:57, il y a 10 mois 30 jours Original-Research: Sernova Corp (von First Berlin Equity Research GmbH): BUY
COMMUNIQUÉ DE PRESSE publié le 14/09/2023 à 22:06, il y a 1 année Sernova Investor Conference Call Previously Scheduled for September 15 Now Rescheduled for September 22
COMMUNIQUÉ DE PRESSE publié le 13/09/2023 à 13:01, il y a 1 année Sernova to Host Investor Calls to Introduce Newly Appointed CEO and Provide Business Update
COMMUNIQUÉ DE PRESSE publié le 03/05/2023 à 13:01, il y a 1 année 4 mois Sernova Announces Research Collaboration with AstraZeneca to Evaluate Novel Potential Therapeutic Cell Applications
COMMUNIQUÉ DE PRESSE publié le 10/04/2023 à 13:05, il y a 1 année 5 mois Sernova to Present at 2023 Alliance for Regenerative Medicine Cell & Gene Meeting on the Med
COMMUNIQUÉ DE PRESSE publié le 22/03/2023 à 12:04, il y a 1 année 5 mois Sernova: Abstract on First Cohort of its Phase 1/2 Study Involving Islet Transplantation into Cell Pouch Selected for Oral Podium Presentation at American Diabetes Association 83rd Scientific Sessions
COMMUNIQUÉ DE PRESSE publié le 14/03/2023 à 12:05, il y a 1 année 6 mois Sernova Announces Upcoming Podium Presentation of iPSC and Cell Pouch™ Combination Treatment for Type One Diabetes at the 4th IPITA / HSCI / JDRF Summit
COMMUNIQUÉ DE PRESSE publié le 08/03/2023 à 13:05, il y a 1 année 6 mois Sernova Announces Initial Islet Transplantation in First Two Patients Enrolled in Second Cohort of its U.S. Phase 1/2 Clinical Trial for Treatment of Type 1 Diabetes
COMMUNIQUÉ DE PRESSE publié le 02/03/2023 à 13:05, il y a 1 année 6 mois Sernova to Participate in Upcoming Roth and Oppenheimer Investor Conferences
Publié le 18/09/2024 à 18:45, il y a 8 heures 25 minutes Augmentation de capital consécutive à l'attribution gratuite d'actions aux salariés du groupe EuropaCorp
Publié le 18/09/2024 à 18:45, il y a 8 heures 25 minutes Capital increase following the allocation of free shares to EuropaCorp employees
Publié le 18/09/2024 à 17:40, il y a 9 heures 31 minutes Groupe CRIT : Modalités de mise à disposition du Rapport Financier semestriel 2024.
Publié le 18/09/2024 à 23:10, il y a 4 heures 1 minute Ur-Energy Provides Operations, Construction and 2024 Guidance Updates
Publié le 18/09/2024 à 23:00, il y a 4 heures 11 minutes Garden State Gold & Coin Applauds Passage of Historic NJ Sales Tax Bill on Precious Metals
Publié le 18/09/2024 à 21:15, il y a 5 heures 56 minutes New to the Street Launches 24-Part Series with ARAX Holdings, Spotlighting Core Blockchain, CorePass, Lunaº Mesh, and Revolutionary Tech Solutions
Publié le 18/09/2024 à 21:00, il y a 6 heures 11 minutes Falcon Commences Drilling At Its Great Burnt Copper Project, NL
Publié le 18/09/2024 à 16:30, il y a 10 heures 41 minutes Manimal Tales Launches New Nursery Rhyme Based Detective Series: Your Child Solves Nursery Crimes in our Newest Personalized Book!
Publié le 18/09/2024 à 19:11, il y a 8 heures EQS-Adhoc: alstria office REIT-AG: squeeze-out demand regarding the shares of minority shareholders, amendment to investment agreement, loss of REIT-status at year-end 2024
Publié le 18/09/2024 à 18:45, il y a 8 heures 26 minutes Fuller, Smith & Turner PLC: Transaction in own shares
Publié le 18/09/2024 à 18:31, il y a 8 heures 39 minutes EQS-Adhoc: Vonovia SE: Initiation of the process to conclude a domination and profit and loss transfer agreement between Vonovia SE and Deutsche Wohnen SE
Publié le 18/09/2024 à 18:13, il y a 8 heures 58 minutes BILENDI: Creating discussion guides for market research is now possible with AI, thanks to BARI and Bilendi Discuss
Publié le 18/09/2024 à 17:21, il y a 9 heures 49 minutes EQS-Adhoc: Marinomed Biotech AG resolves capital increase excluding statutory subscription rights by issuing 154,053 no-par value bearer shares at an issue price of EUR 5 per share